Evommune Inc saw its shares tumble 27% in after-hours trading Tuesday after announcing that EVO756 failed to meet both the primary and secondary endpoints in a Phase 2b trial for atopic dermatitis.
The randomized, double-blind, placebo-controlled study enrolled 121 adults with moderate-to-severe atopic dermatitis and ran over a 12-week treatment period. The trial did not meet its primary endpoint, defined as the percent change from baseline in the Eczema Area and Severity Index score at Week 12, across any of the doses evaluated. Secondary endpoints were also not achieved.
Following these results, Evommune said it will not advance EVO756 in atopic dermatitis. The company described EVO756 as an oral Mas-related G-protein coupled receptor X2 antagonist that was generally well tolerated in the study, with a safety profile consistent with earlier trials. Evommune added that it will continue development of EVO756 in a separate indication, specifically migraine prophylaxis, where Phase 2b work remains ongoing.
Evommune said it will promote EVO301, an interleukin-18 binding protein fusion molecule, to be its lead program for atopic dermatitis. That decision follows positive Phase 2a proof-of-concept data for EVO301, and the firm plans a Phase 2b trial for that candidate in mid-2027.
Company executives framed the outcome as a setback for EVO756 in atopic dermatitis but not for the broader pipeline. "We are disappointed that this trial of EVO756 did not meet its primary endpoint, particularly given the need for new treatment options for patients suffering from AD," said Dr. Eugene Bauer, Chief Medical Officer of Evommune. Luis Peña, President and Chief Executive Officer, said the company maintains a strong balance sheet supporting operations into 2029 and remains focused on advancing its portfolio of programs addressing chronic inflammatory diseases.
Context and implications
From a portfolio management perspective, Evommune has chosen to reallocate atopic dermatitis leadership to EVO301 after the negative Phase 2b readout for EVO756. The company also kept open a separate development path for EVO756 in migraine prophylaxis, indicating the molecule's program-specific failure rather than a wholesale safety concern, given the reported tolerability profile.
Market reaction
The stock price movement in after-hours trading reflects immediate investor reassessment of the asset's value for the atopic dermatitis indication. Management emphasized the firms cash runway into 2029 as support for ongoing operations and pipeline advancement despite the clinical setback.
Key points
- EVO756 failed to meet the primary endpoint and secondary endpoints in a 12-week Phase 2b trial of 121 adults with moderate-to-severe atopic dermatitis.
- Evommune will not advance EVO756 for atopic dermatitis but will continue exploring EVO756 in migraine prophylaxis and will advance EVO301 as the lead atopic dermatitis program with a Phase 2b planned for mid-2027.
- The company reported that EVO756 was generally well tolerated and that its balance sheet supports operations into 2029; the stock fell 27% in after-hours trading following the trial results.
Risks and uncertainties
- Clinical development risk - EVO756 did not meet efficacy endpoints in this Phase 2b, illustrating the risk that late-stage trials may fail to confirm earlier expectations; this affects the biotech and healthcare sectors.
- Program timing and execution - While EVO301 is slated for a Phase 2b in mid-2027, that timeline represents an uncertainty for future atopic dermatitis data readouts and market impact; this affects development timelines in biotech and related equity valuations.
- Market confidence - The sharp after-hours stock decline highlights investor sensitivity to clinical outcomes, introducing volatility risk for Evommune shares and peer small-cap clinical-stage biotech stocks.